Attending Biotech and Pharma
BOS 2008 Programme
BOS is primarily a partnering event; a forum to connect UK biotech outsourcing executives with a network of specialist CROs operating at the discovery/development interface. In addition to 1 to 1 partnering we have organised a programme of speakers who will deliver perspective and experience from academia, industry and the service sector.
We are pleased to announce a first class programme of speakers for BOS 2008 including the following experts in their fields; Julie Warneck from Serentis Ltd will be opening proceedings with a talk on biotech approaches to discovery biology and pharmacology and the role played by outsourcing in their approach to R&D; Dr Ming-Qiang Zhang of Biotica Technologies Ltd will then be providing his unique perspective on the medicinal chemistry employed by Biotica using microbes in addition to the more traditional contract chemistry route. After the Technology Showcase and one to one partnering meetings held during the lunch interval we are pleased to welcome Dr Paul Little from 7TM Pharma in Denmark who will be giving his perspective on managing the CMC challenges associated with early stage NCE development in a biotech environment and how outsourcing plays it's role at 7TM. Following NCE R&D downstream we are pleased to have Dr Chris Roe from AstraZeneca share his experiences of different preformulation strategies that have helped AstraZeneca progress candidates toward 1st in man. Finally after the coffee break Dr Lloyd Payne, CSO from biotech F2G Ltd, will share with us his experiences of working with CRAM from the East and West respectively and comment on some of the key considerations when looking to outsourc to India or China or closer to home in Europe.
| Provisional Programme: Biotech Outsource Strategies 2008 |
|
|---|---|
| 07.30 - 09.30 | Partnering Breakfast and Registration
Partnering breakfast sponsored by Novamass |
| 09.30 - 11.00 | Chair of Discovery Session
Duncan B Judd, Manager, Discovery Medicinal Chemistry, GlaxoSmithKline |
| 09.30 - 10.15 | Utilising microbial chemistry & human chemists (CROs) to create a biosynthetic medicinal chemistry platform for next generation Polyketides
Dr Ming-Qiang Zhang, Senior Vice President, Research & Development, Biotica |
| 10.15 - 11.00 | Managing the discovery and development interface and outsourcing challenges faced by an emerging biotech
Martin Cooper, Development Manager, 7TM Pharma |
| 11.00 - 11.30 | Coffee Break |
| 11.30 - 12.30 | Chair of Technology Showcase
Dr Steve Shuttleworth, Karus Therapeutics Ltd |
| 11.30 - 11.40 | Innovative chemistry to accelerate research
Ed Dutton, Peakdale Molecular |
| 11.40 - 11.50 | Manufacture of high potent compounds for clinical development
David Bormett, SAFC Pharma |
| 11.50 - 12.00 | High-throughput crystallizations
Dr Philippe Fernandes, Onyx Scientific |
| 12.00 - 12.10 | Steps ahead through solid state research
Pauline Jaeger, Avantium Technologies |
| 12.10 - 12.20 | Innovative chiral technologies from Piramal Healthcare - improving speed, robustness, cost and waste in API and intermediate production
Dr John Blacker, Piramal Healthcare |
| 12.20 - 12.30 | Advanced pharmaceutical analysis
Dr Ben Cliff, Intertek ASG |
| 12.30 - 14.00 | Lunch, Networking & Partnering Meetings |
| 14.00 - 15.30 | Chair of Early Development Session
Dr Peter Hudson, Director of Pharmaceutical Development, Acadia Pharmaceuticals AB |
| 14.00 - 14.45 | Analytical method development within a biotech setting and managing contractor relationships to achieve success
Dr Roland Collicott, ChalPharm Consultancy |
| 14.45 - 15.30 | Accelerating the pathway to first in man studies through rational selection of formulations for NCE R&D
Dr Maria Marlow, Team Manager- Early Development, Pharmaceutical and Analytical R&D, AstraZeneca |
| 15.30 - 16.00 | Coffee Break & Partnering |
| 16.00 - 17.00 | Chair of Case Study Session
Dr Chris Hill, Senior Vice President Research, Organon Laboratories Ltd |
| 16.00 - 17.00 | Managing outsource alliances in the East and West, respective strengths and weakness’ and strategies to ensure success
Dr Lloyd Payne, CSO, F2G Ltd |
Key Sponsors
Gold CRO Sponsors
Silver CRO Sponsor
Corporate Sponsor
